PriceTargets.com logo

Outlook Therapeutics - OTLK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $46.43
  • Forecasted Upside: 465.47%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$8.21 As of 04/24/2024 01:26 PM ET
▲ +0.01 (0.12%)

This chart shows the closing price for OTLK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Outlook Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OTLK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OTLK

Analyst Price Target is $46.43
▲ +465.47% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Outlook Therapeutics in the last 3 months. The average price target is $46.43, with a high forecast of $100.00 and a low forecast of $20.00. The average price target represents a 465.47% upside from the last price of $8.21.

This chart shows the closing price for OTLK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 polled investment analysts is to moderate buy stock in Outlook Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2024BTIG ResearchUpgradeNeutral ➝ Buy$50.00Low
3/25/2024HC WainwrightBoost TargetBuy ➝ Buy$30.00Low
2/16/2024Capital One FinancialReiterated RatingOverweightLow
2/15/2024Chardan CapitalUpgradeNeutral ➝ Buy$60.00Low
1/25/2024Brookline Capital ManagementUpgradeHold ➝ Buy$31.40Low
1/25/2024GuggenheimUpgradeNeutral ➝ Buy$40.00Low
12/29/2023Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$30.00 ➝ $40.00Low
12/27/2023Capital One FinancialUpgradeEqual Weight ➝ Overweight$100.00Low
11/3/2023HC WainwrightUpgradeNeutral ➝ Buy$20.00 ➝ $40.00N/A
8/31/2023Chardan CapitalDowngradeBuy ➝ NeutralLow
8/31/2023HC WainwrightDowngradeBuy ➝ Neutral$100.00 ➝ $20.00Low
8/30/2023Brookline Capital ManagementDowngradeBuy ➝ HoldLow
8/30/2023Capital One FinancialDowngradeOverweight ➝ Equal WeightN/A
8/30/2023GuggenheimDowngradeBuy ➝ NeutralN/A
8/30/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$90.00 ➝ $20.00N/A
8/30/2023BTIG ResearchDowngradeBuy ➝ NeutralN/A
8/15/2023Chardan CapitalReiterated RatingBuy ➝ Buy$200.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00Low
7/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00Low
7/13/2023Capital One FinancialInitiated CoverageOverweight$100.00Low
4/3/2023GuggenheimInitiated CoverageBuy$100.00Low
2/15/2023HC WainwrightReiterated RatingBuy$100.00Low
2/6/2023Cantor FitzgeraldInitiated CoverageOverweight$80.00Low
1/6/2023HC WainwrightLower TargetBuy$120.00 ➝ $100.00Low
10/31/2022BTIG ResearchInitiated CoverageBuy$140.00Low
10/3/2022Brookline Capital ManagementReiterated RatingBuyLow
9/13/2022Chardan CapitalInitiated CoverageBuyLow
8/22/2022Ascendiant Capital MarketsLower Target$140.00Low
12/23/2021HC WainwrightReiterated RatingBuy$120.00Low
8/3/2021HC WainwrightBoost TargetBuy$100.00 ➝ $120.00High
2/17/2021LADENBURG THALM/SH SHReiterated RatingBuy$120.00Low
8/27/2020HC WainwrightLower TargetBuy$140.00 ➝ $100.00High
8/18/2020OppenheimerLower TargetOutperform$180.00 ➝ $160.00Low
6/4/2020LADENBURG THALM/SH SHReiterated RatingBuy$120.00Medium
6/3/2020OppenheimerInitiated CoverageBuy$180.00Medium
5/27/2020HC WainwrightLower TargetBuy$160.00 ➝ $140.00High
5/18/2020HC WainwrightReiterated RatingBuy$160.00Medium
5/18/2020OppenheimerReiterated RatingBuyHigh
5/5/2020Brookline Capital ManagementInitiated CoverageBuyHigh
4/14/2020HC WainwrightReiterated RatingBuyHigh
9/11/2019LADENBURG THALM/SH SHInitiated CoverageBuy$180.00High
7/18/2019HC WainwrightInitiated CoverageBuy$160.00High
5/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$240.00High
5/16/2019OppenheimerInitiated CoverageOutperform$240.00 ➝ $240.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
9/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 5 very positive mentions
  • 27 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 4 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
12/26/2023
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 10 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 11 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 8 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 8 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Outlook Therapeutics logo
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Read More

Today's Range

Now: $8.21
Low: $8.00
High: $8.66

50 Day Range

MA: $8.60
Low: $5.73
High: $11.94

52 Week Range

Now: $8.21
Low: $4.00
High: $40.60

Volume

149,003 shs

Average Volume

532,747 shs

Market Capitalization

$106.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Outlook Therapeutics?

The following equities research analysts have issued stock ratings on Outlook Therapeutics in the last twelve months: Ascendiant Capital Markets, Brookline Capital Management, BTIG Research, Cantor Fitzgerald, Capital One Financial Co., Chardan Capital, Guggenheim, and HC Wainwright.
View the latest analyst ratings for OTLK.

What is the current price target for Outlook Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Outlook Therapeutics in the last year. Their average twelve-month price target is $46.43, suggesting a possible upside of 465.5%. Capital One Financial Co. has the highest price target set, predicting OTLK will reach $100.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $20.00 for Outlook Therapeutics in the next year.
View the latest price targets for OTLK.

What is the current consensus analyst rating for Outlook Therapeutics?

Outlook Therapeutics currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OTLK.

What other companies compete with Outlook Therapeutics?

Other companies that are similar to Outlook Therapeutics include bluebird bio, BioAtla, aTyr Pharma, Vigil Neuroscience and Sangamo Therapeutics. Learn More about companies similar to Outlook Therapeutics.

How do I contact Outlook Therapeutics' investor relations team?

Outlook Therapeutics' physical mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The company's listed phone number is (609) 619-3990 and its investor relations email address is [email protected]. The official website for Outlook Therapeutics is www.outlooktherapeutics.com. Learn More about contacing Outlook Therapeutics investor relations.